Edition:
United States

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.92USD
18 May 2018
Change (% chg)

$-0.01 (-0.17%)
Prev Close
$5.93
Open
$5.95
Day's High
$6.00
Day's Low
$5.86
Volume
88,754
Avg. Vol
186,736
52-wk High
$9.69
52-wk Low
$3.83

Chart for

About

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low... (more)

Overall

Beta: --
Market Cap(Mil.): $276.04
Shares Outstanding(Mil.): 44.31
Dividend: --
Yield (%): --

Financials

  PIRS.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.71 -- --
ROI: -55.96 1.57 14.38
ROE: -132.26 2.43 16.07

BRIEF-Pieris Pharmaceuticals Reports Q1 Loss Per Share $0.17

* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 10 2018

BRIEF-Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share

* PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING

Feb 14 2018

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

Feb 09 2018

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

Feb 09 2018

BRIEF-Pieris Pharma Doses First Subjects In Phase I Study Of PRS-060

* PIERIS PHARMACEUTICALS-DOSED FIRST SUBJECTS IN PHASE I STUDY OF PRS-060, TRIGGERING $12.5 MILLION MILESTONE PAYMENT FROM ASTRAZENECA TO CO-SEC FILING Source text: (http://bit.ly/2oXTLTa) Further company coverage:

Dec 20 2017

BRIEF-Pieris Pharma Received Clearance to Initiate Its First-In-Human Study In Australia For PRS-060/AZD1402

* PIERIS PHARMACEUTICALS - RECEIVED ETHICS AND REGULATORY CLEARANCE TO INITIATE ITS FIRST-IN-HUMAN STUDY IN AUSTRALIA FOR PRS-060/AZD1402

Dec 07 2017

Earnings vs. Estimates